Ilsung Is Co., Ltd.

KOSE:A003120 Stock Report

Market Cap: ₩142.2b

Ilsung Is Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ilsung Is.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth23.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Nov 23

We Like The Quality Of Ilsung Is' (KRX:003120) Earnings

Ilsung Is Co., Ltd.'s ( KRX:003120 ) recent earnings report didn't offer any surprises, with the shares unchanged over...
Analysis Article • Jul 14

Ilsung Is Co., Ltd.'s (KRX:003120) 27% Price Boost Is Out Of Tune With Revenues

Ilsung Is Co., Ltd. ( KRX:003120 ) shares have continued their recent momentum with a 27% gain in the last month alone...
Analysis Article • May 30

Optimistic Investors Push Ilsung Is Co., Ltd. (KRX:003120) Shares Up 26% But Growth Is Lacking

The Ilsung Is Co., Ltd. ( KRX:003120 ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • May 23

Solid Earnings May Not Tell The Whole Story For Ilsung Is (KRX:003120)

Ilsung Is Co., Ltd.'s ( KRX:003120 ) robust recent earnings didn't do much to move the stock. We think this is due to...
Analysis Article • Feb 20

Reflecting on Ilsung Pharmaceuticals' (KRX:003120) Share Price Returns Over The Last Three Years

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
Analysis Article • Jan 16

Ilsung Pharmaceuticals (KRX:003120) Is Growing Earnings But Are They A Good Guide?

As a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...
Analysis Article • Dec 18

Here's What Ilsung Pharmaceuticals Co., Ltd.'s (KRX:003120) Shareholder Ownership Structure Looks Like

Every investor in Ilsung Pharmaceuticals Co., Ltd. ( KRX:003120 ) should be aware of the most powerful shareholder...
Analysis Article • Nov 21

Reflecting on Ilsung Pharmaceuticals' (KRX:003120) Share Price Returns Over The Last Three Years

Many investors define successful investing as beating the market average over the long term. But if you try your hand...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ilsung Is has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A003120 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202664,3811,204-614928N/A
12/31/202564,2921,1661,8113,881N/A
9/30/202566,5082,323-4,7736,873N/A
6/30/202568,76511,600-10,98870N/A
3/31/202569,65315,299-14,929-4,127N/A
12/31/202469,01813,094-16,342-4,256N/A
9/30/202474,170-11,779-42,233-36,494N/A
6/30/202473,225-20,182-45,349-37,456N/A
3/31/202476,110-16,528-61,289-52,085N/A
12/31/202378,053-20,941-49,168-41,475N/A
9/30/202373,179891-405,953-343,354N/A
6/30/202371,0942,959-392,071-331,679N/A
3/31/202364,11099,631-89,436-26,239N/A
12/31/202261,248105,241-101,462-38,966N/A
9/30/202256,672107,092284,897294,625N/A
6/30/202251,288104,560278,883292,140N/A
3/31/202248,3684,809-9,2033,107N/A
12/31/202142,090-1,368-6,9145,704N/A
9/30/202139,735-2,747-7,6253,703N/A
6/30/202138,899-2,851-6,3061,580N/A
3/31/202138,226-2,977-2,5152,600N/A
12/31/202040,6013,220-3,2601,557N/A
9/30/202043,3284,4654,0045,373N/A
6/30/202044,7683,49116,43617,573N/A
3/31/202047,6586,9001,9823,009N/A
12/31/201948,4126,719N/A4,389N/A
9/30/201951,7603,982N/A11,395N/A
6/30/201952,5514,198N/A-329N/A
3/31/201955,9691,509N/A15,951N/A
12/31/201861,6532,946N/A15,091N/A
9/30/201861,2202,386N/A9,663N/A
6/30/201865,7242,936N/A10,193N/A
3/31/201867,4162,497N/A7,472N/A
12/31/201767,0432,629N/A10,159N/A
9/30/201768,4243,709N/A3,922N/A
6/30/201769,2603,292N/A6,628N/A
3/31/201768,0703,848N/A-14,404N/A
12/31/201667,4633,017N/A-31,013N/A
9/30/201666,04096,725N/A-25,114N/A
6/30/201663,56197,016N/A-26,735N/A
3/31/201662,76697,235N/A-8,300N/A
12/31/201561,74598,854N/A6,041N/A
9/30/201561,7905,071N/A6,388N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A003120's forecast earnings growth is above the savings rate (3.3%).

Earnings vs Market: Insufficient data to determine if A003120's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A003120's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A003120's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A003120's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A003120's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/10 12:36
End of Day Share Price 2026/08/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ilsung Is Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.